Compositions and methods directed to treating liver fibrosis

1. A double-stranded ribonucleic acid (dsRNA) for inhibiting expression of TGFβ, wherein said dsRNA comprises a sense strand and an antisense strand, the sense strand comprising one of SEQ ID NOs: 63, 65, 69, 75, 77, 85, 91, 93, 99 and 105, and the antisense strand comprising, respectively, one of SEQ ID NOs: 64, 66, 70, 76, 78, 86, 92, 94, 100 and 106.

2. The dsRNA of claim 1 , wherein each strand is no more than 30 nucleotides in length.

3. The dsRNA of claim 1 , wherein at least one strand comprises a 3′ overhang of at least 1 nucleotide.

4. The dsRNA of claim 1 , further comprising a ligand.

5. The dsRNA of claim 4 , wherein the ligand is conjugated to the 3′ end of the sense strand of the dsRNA.

6. A cell containing the dsRNA of claim 1 .

7. A pharmaceutical composition for inhibiting expression of a TGFβ gene comprising the dsRNA of claim 1 .

8. A lipid formulation comprising a dsRNA of claim 1 .

9. The lipid formulation of claim 8 , wherein the lipid formulation is a SNALP, or XTC formulation.

10. A vector encoding a dsRNA, wherein said dsRNA comprises a sense strand and an antisense strand, the sense strand comprising a nucleobase sequence selected from the group consisting of SEQ ID NOs: 63, 65, 69, 75, 77, 85, 91, 93, 99 and 105, and the antisense strand comprising, respectively, a nucleobase sequence selected from the group consisting of SEQ ID NOs: 64, 66, 70, 76, 78, 86, 92, 94, 100 and 106.

11. A cell comprising the vector of claim 10 .

12. The double-stranded ribonucleic acid of claim 1 , wherein the sense strand comprises SEQ ID NO: 69 and the antisense strand comprises SEQ ID NO: 70.

13. The double-stranded ribonucleic acid of claim 1 , wherein the sense strand comprises SEQ ID NO: 91 and the antisense strand comprises SEQ ID NO: 92.